Navigating the complexities of rAAV vector manufacturing can be daunting for small and mid-sized biotech companies venturing into the exciting world of gene therapy. Ensuring consistent quality and optimizing production processes are paramount for success.

Step inside DINAMIQS’ largest expansion project to date, a brand new, 2,500 square meter cGMP facility designed for viral vector production. This new facility will enable us to scale up production to 1000L, providing product for R&D, clinical use and commercial manufacturing under one roof.